Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.

Westerhout, Kirsten Y; Bouwmeester, Walter; Duchesne, Inge; Pisini, Marta; Piena, Marjanne A; Damele, Francesco; Gueron, Beatrice; Treur, Maarten; Belsey, Jonathan

Westerhout, Kirsten Y; Bouwmeester, Walter; Duchesne, Inge; Pisini, Marta; Piena, Marjanne A; Damele, Francesco; Gueron, Beatrice; Treur, Maarten; Belsey, Jonathan.

Afiliação

Westerhout KY; Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands.
Bouwmeester W; Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands.
Duchesne I; Janssen EMEA, Turnhoutseweg, Beerse, Belgium.
Pisini M; Janssen EMEA, Turnhoutseweg, Beerse, Belgium.
Piena MA; Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands.
Damele F; Janssen-Cilag SpA, Via Michelangelo Buonarroti, Cologno Monzese, Italy.
Gueron B; Janssen EMEA, Turnhoutseweg, Beerse, Belgium.
Treur M; Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands.
Belsey J; JB Medical Ltd, Old Brickworks, Little Cornard, United Kingdom.

Clinicoecon Outcomes Res ; 9: 163-172, 2017.

Article em En | MEDLINE | ID: mdl-28280374

Palavras-chave

NS5A inhibitor; health economics; hepatitis C; ledipasvir; simeprevir; sofosbuvir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google